Stockreport

Clene stock rallies 52% post-market on MS drug data [Seeking Alpha]

Clene Inc.  (CLNN) 
PDF Clene said data from the long-term extension of its Phase 2 VISIONARY-MS study showed significant evidence of repair and remyelination across multiple paraclinical endp [Read more]